Managed Account Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Managed Account Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$189M	Buy	1,535,826 +296,346	+24%	+$35.5M	0.16%	166
2015 Q1	$142M	Buy	1,239,480 +315,147	+34%	+$34.8M	0.12%	192
2014 Q4	$93.5M	Buy	924,333 +187,986	+26%	+$18.3M	0.09%	255
2014 Q3	$67.2M	Buy	736,347 +229,641	+45%	+$20.2M	0.07%	312
2014 Q2	$43.4M	Buy	506,706 +196,995	+64%	+$15.5M	0.05%	399
2014 Q1	$24.4M	Buy	309,711 +112,053	+57%	+$9.34M	0.03%	588
2013 Q4	$15M	Buy	197,658 +35,598	+22%	+$2.53M	0.02%	757
2013 Q3	$11.3M	Buy	162,060 +13,344	+9%	+$874K	0.02%	849
2013 Q2	$8.62M	Buy	+148,716	New	+$8.6M	0.01%	939

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Managed Account Advisors's IBB Position: Q2 2015 in Review

Managed Account Advisors increased its iShares Biotechnology ETF (IBB) stake by 24% in Q2 2015, buying an estimated $35.5M and bringing the position to 1,535,826 shares worth $189M. The position accounts for 0.16% of the portfolio, ranked #166.

Managed Account Advisors first reported a position in IBB in Q2 2013 and has held it in 9 quarters since. 419 funds tracked by Wall St. Rank hold IBB as of Q2 2015.

Managed Account Advisors held 1,535,826 shares of iShares Biotechnology ETF worth $189M as of Q2 2015.
Managed Account Advisors bought 296,346 iShares Biotechnology ETF shares in Q2 2015, an estimated $35.5M.
iShares Biotechnology ETF made up 0.16% of Managed Account Advisors's portfolio in Q2 2015, its #166 holding.
Managed Account Advisors first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 9 quarters since.
419 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.